Fisher & Paykel Healthcare Corporation Limited

OTCPK:FSPK.F Stock Report

Market Cap: US$12.6b

Fisher & Paykel Healthcare Valuation

Is FSPK.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of FSPK.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: FSPK.F ($20.2) is trading above our estimate of fair value ($11.98)

Significantly Below Fair Value: FSPK.F is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for FSPK.F?

Key metric: As FSPK.F is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for FSPK.F. This is calculated by dividing FSPK.F's market cap by their current revenue.
What is FSPK.F's PS Ratio?
PS Ratio13x
SalesNZ$1.74b
Market CapNZ$21.66b

Price to Sales Ratio vs Peers

How does FSPK.F's PS Ratio compare to its peers?

The above table shows the PS ratio for FSPK.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2.9x
BAX Baxter International
1.1x-2.4%US$16.8b
HOLX Hologic
4.6x4.9%US$18.3b
TFX Teleflex
2.9x5.2%US$8.9b
ZBH Zimmer Biomet Holdings
2.9x4.3%US$21.6b
FSPK.F Fisher & Paykel Healthcare
13x10.8%US$21.7b

Price-To-Sales vs Peers: FSPK.F is expensive based on its Price-To-Sales Ratio (13x) compared to the peer average (2.9x).

Price to Sales Ratio vs Industry

How does FSPK.F's PS Ratio compare vs other companies in the US Medical Equipment Industry?

50 CompaniesPrice / SalesEstimated GrowthMarket Cap
INGN Inogen
0.7x4.2%US$219.37m
ARAY Accuray
0.4x5.5%US$190.07m
NVRO Nevro
0.4x2.5%US$163.38m
KEQU Kewaunee Scientific
0.6xn/aUS$122.28m
FSPK.F 13.0xIndustry Avg. 3.2xNo. of Companies50PS02.85.68.411.214+
50 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: FSPK.F is expensive based on its Price-To-Sales Ratio (13x) compared to the US Medical Equipment industry average (3.2x).

Price to Sales Ratio vs Fair Ratio

What is FSPK.F's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

FSPK.F PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio13x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate FSPK.F's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst FSPK.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
US$18.29
0%
20.4%US$24.51US$11.81n/a13
Nov ’25US$20.20
US$19.62
-2.9%
19.3%US$24.88US$12.78n/a13
Oct ’25n/a
US$19.62
0%
19.3%US$24.88US$12.78n/a13
Sep ’25US$22.00
US$18.68
-15.1%
18.7%US$23.91US$12.61n/a13
Aug ’25n/a
US$15.40
0%
12.3%US$19.51US$11.98n/a13
Jul ’25US$18.25
US$15.95
-12.6%
11.9%US$20.16US$12.38n/a14
Jun ’25US$18.17
US$15.95
-12.2%
11.9%US$20.16US$12.38n/a14
May ’25n/a
US$14.33
0%
10.0%US$17.28US$10.93n/a14
Apr ’25n/a
US$14.29
0%
9.5%US$17.03US$10.99n/a14
Mar ’25US$14.64
US$13.38
-8.6%
9.0%US$15.15US$11.15n/a14
Feb ’25US$14.38
US$13.43
-6.6%
9.1%US$15.28US$11.24n/a14
Jan ’25n/a
US$13.61
0%
8.7%US$15.39US$11.33n/a14
Dec ’24US$14.46
US$13.61
-5.9%
8.7%US$15.39US$11.33n/a14
Nov ’24US$12.00
US$13.41
+11.7%
7.9%US$15.11US$11.76US$20.2012
Oct ’24US$12.70
US$13.36
+5.2%
6.9%US$14.90US$11.92n/a12
Sep ’24US$13.04
US$13.85
+6.2%
10.8%US$16.76US$11.94US$22.0012
Aug ’24n/a
US$14.26
0%
12.0%US$17.01US$12.11n/a11
Jul ’24n/a
US$14.26
0%
12.0%US$17.01US$12.11US$18.2511
Jun ’24US$14.75
US$14.26
-3.3%
12.0%US$17.01US$12.11US$18.1711
May ’24US$16.69
US$14.83
-11.2%
12.5%US$17.82US$12.29n/a11
Apr ’24n/a
US$15.62
0%
12.1%US$18.85US$13.00n/a11
Mar ’24US$16.07
US$15.62
-2.8%
12.1%US$18.85US$13.00US$14.6411
Feb ’24US$16.49
US$15.62
-5.3%
12.1%US$18.85US$13.00US$14.3811
Jan ’24n/a
US$14.22
0%
12.4%US$17.02US$11.72n/a12
Dec ’23US$15.40
US$14.17
-8.0%
10.4%US$16.40US$11.73US$14.4611
Nov ’23US$11.72
US$11.76
+0.3%
13.4%US$14.46US$9.51US$12.0010

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

Elevance Health

US$92.2b

Operates as a health benefits company in the United States.

ELV

US$403.60

7D

-0.8%

1Y

-15.9%

Centene

US$29.8b

Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.

CNC

US$60.35

7D

2.8%

1Y

-18.7%

electroCore

US$64.1m

A commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally.

ECOR

US$9.92

7D

-27.1%

1Y

80.4%